20世纪50年代起,陆续研发出了较为有效的抗真菌药物,如灰黄霉素。直到20世纪60年代,氟胞嘧啶被引入,其抗菌谱局限于念珠菌属和隐球菌,并仅用于与两性霉素B(AmB)联合治疗。
进入新世纪后,唑类抗真菌药物的发展迎来了新纪元。这类药物减少了毒性,提高了抗真菌效力。第一个唑类药物是克霉唑,主要用于局部黏膜及皮肤念珠菌感染;第二个则是咪康唑,如今几乎仅用于局部治疗。直到20世纪70年代中期,酮康唑的研制成功标志着重要突破——口服对深部真菌感染有效,并且抗菌谱广、毒性有所减小,被视为抗真菌药物发展过程中的革命性进展。然而,由于重症患者无法口服吸收、中枢神经系统穿透力差及抗真菌活性不足等问题,酮康唑的临床应用受到了限制。
20世纪80年代后期,伊曲康唑和氟康唑等新药的开发显著改善了抗菌谱和生物利用度,它们的出现标志着抗真菌治疗进入了一个崭新时代。尽管如此,没有一种药物能够实现绝对杀真菌的效果。近年来,耐药菌株日益增多,加之药物毒性反应的限制,使得真菌感染治疗面临诸多挑战。
目前较有希望的药物包括抑制胞膜麦角固醇合成和干扰胞壁β-葡聚糖合成的药物,如氟康唑、伊曲康唑和睫状真菌素。此外,那些抗菌力强及毒性作用大的老药也在不断改进中。联合用药成为抗真菌治疗的方向之一。
中文名称 | 英文名称 | CAS号 | 化学式 | 结构式图片 |
---|---|---|---|---|
奥泽沙星 | ozenoxacin | 245765-41-7 | C21H21N3O3 |
|
奥克太啶 | N,N'-(1,10 decanediyldi-1[4H]-pyridinyl-4-ylidene)-bis-(1-octanamine) | 71251-02-0 | C36H62N4 |
|
头孢磺啶钠 | 52152-93-9 | C22H20N4NaO8S2 |
|
|
噻康唑 | tioconazole | 65899-73-2 | C16H13Cl3N2OS |
|
咪康唑 | miconazole | 22916-47-8 | C18H14Cl4N2O |
|
吖啶琐辛 | Acrisorcin | 7527-91-5 | C12H18O2*C13H10N2 |
|
卢立康唑 | luliconazole | 187164-19-8 | C14H9Cl2N3S2 |
|
利奈唑胺 | linezolid | 165800-03-3 | C16H20FN3O4 |
|
伏立康唑 | voriconazole | 188416-29-7 | C16H14F3N5O |
|
伊曲康唑-d5 | Itraconazole-d5 (major) | 84625-61-6 | C35H38Cl2N8O4 |
|
NSC 317629; 1-[4-[4-[[2-(2,4-二氯苯基)-2-(1H-咪唑-1-甲基)-1,3-二氧杂环戊-4-基]甲氧基]苯基]-1-哌嗪基]乙酮 | ketokonazole | 65277-42-1 | C26H28Cl2N4O4 |
|
L-肌肽锌 | zinc carnosine | 107667-60-7 | C9H12N4O3Zn |
|
5-溴-5-硝基-1,3-二恶烷 | bronidox | 30007-47-7 | C4H6BrNO4 |
|
2-辛基-4-异噻唑啉-3-酮 | 2-octyl-isothiazol-3-one | 26530-20-1 | C11H19NOS |
|
2,3,6-三溴对甲酚 | 2,4,6-tribromo-m-cresol | 4619-74-3 | C7H5Br3O |
|
(Z)-2'-(1-咪唑基)-O-(2,4-二氯苄基)-2,4-二氯苯乙酮肟硝酸盐 | Oxiconazole Nitrate | 64211-46-7 | C18H14Cl4N4O4 |
|
(E)-1-(5-氯-2-噻吩基-2-(1H)-咪唑-1-基)乙酮(2,6-二氯苯基)腙盐酸盐 | (E)-1-(5-chlorothien-2-yl)-2-(1H-imidazol-1-yl)ethanone 2,6-dichlorophenylhydrazone hydrochloride | 80168-44-1 | C15H11Cl3N4S*ClH |
|
—— | Spectinomycin dihydrochloride pentahydrate | 22189-32-8 | C14H27ClN2O8 |
|
—— | 85960-17-4 | C28H43N5NaO9S2 |
|
|
—— | Pharmakon1600-01500201 | 642-78-4 | C19H18ClN3NaO5S+ |
|
—— | Phleomycin | 11006-33-0 | C51H75N17O21S2 |
|
—— | 1-(2,4-Dichloro-phenyl)-2-imidazol-1-yl-ethanone O-(2,4-dichloro-benzyl)-oxime; compound with nitric acid | 64211-46-7 | C18H13Cl4N3O*HNO3 |
|
—— | Dihydrostreptomycin Sulfate | 1425-61-2 | C42H88N14O36S3 |
|
—— | Siccanin | 22733-60-4 | C22H30O3 |
|
—— | decanoyl-Trp-D-Asn-Asp-Thr(1)-Gly-Orn-Asp-D-Ala-Asp-Gly-D-Ser-Glu(3S-Me)-Asp(Ph(2-NH2))-(1) | 103060-53-3 | C72H101N17O26 |
|
—— | (E)-1-(2,4-dichlorophenyl)-N-[(2,4-dichlorophenyl)methoxy]-2-imidazol-1-ylethanimine;nitric acid | 64211-46-7 | C18H14Cl4N4O4 |
|
—— | 1-(2,4-dichlorophenyl)-N-[(2,4-dichlorophenyl)methoxy]-2-(1-imidazolyl)ethanimine | 64211-46-7 | C18H13Cl4N3O |
|
—— | Bafilomycin A | 116764-51-3 | C35H58O9 |
|
—— | Setamycin | 88899-56-3 | C44H65NO13 |
|
—— | Cloxacillin(1-) | 642-78-4 | C19H17ClN3O5S- |
|
—— | Ketocanazole | 65277-42-1 | C26H28Cl2N4O4 |
|
—— | (1S,4S,13S,16S,19R,22S,25S,28R,31S,37S,40R,41R,44R,47S,50S,53R,56R,65S,70R)-44-amino-47-(4-aminobutyl)-37-(2-amino-2-oxoethyl)-50-(3-amino-3-oxopropyl)-4,16,22-tribenzyl-31-[(R)-carboxy(hydroxy)methyl]-41,70-dimethyl-2,5,8,14,17,20,23,26,29,32,35,38,45,48,51,54,57,67-octadecaoxo-25-propan-2-yl-42,69,72-trithia-3,6,9,15,18,21,24,27,30,33,36,39,46,49,52,55,58,60,66-nonadecazapentacyclo[38.18.9.319,56.328,53.09,13]triheptacontane-65-carboxylic acid | 1391-36-2 | C89H125N23O25S3 |
|
—— | Cefsulodin sodium salt hydrate, third-generation cephalosporin antibiotic | 52152-93-9 | C22H21N4NaO8S2+ |
|
—— | (2R)-2-[[(2S)-5-(diaminomethylideneamino)-1-[[(2R)-1-[[(2S)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopentan-2-yl]carbamoylamino]-3-phenylpropanoic acid | 37691-11-5 | C27H44N10O6 |
|
—— | decanoyl-Trp-D-Asn-Asp-Thr(1)-Gly-D-Orn-Asp-Ala-Asp-Gly-D-Ser-Glu(3S-Me)-Asp(Ph(2-NH2))-(1) | 103060-53-3 | C72H101N17O26 |
|
—— | (3E,5E,7R,8S,9S,11E,13E,15S,16R)-16-[(2S,3R,4S)-4-[(2R,4R,5S,6R)-2,4-dihydroxy-5-methyl-6-propan-2-yloxan-2-yl]-3-hydroxypentan-2-yl]-8-hydroxy-3,15-dimethoxy-5,7,9,11-tetramethyl-1-oxacyclohexadeca-3,5,11,13-tetraen-2-one | 88899-55-2 | C35H58O9 |
|
—— | Pharmakon1600-01502029 | 52152-93-9 | C22H20N4NaO8S2+ |
|
—— | Oxytetracycline dihydrate | 6153-64-6 | C22H28N2O11 |
|
—— | Daptomycin (LY146032) | 103060-53-3 | C72H101N17O26 |
|
—— | (3S)-2-(2,4-Difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol | 137234-62-9 | C16H14F3N5O |
|
—— | Bafilomycin B1 | 88899-56-3 | C44H65NO13 |
|
—— | decanoyl-Trp-Asn-Asp-DL-xiThr(1)-Gly-D-Orn-Asp-D-Ala-Asp-Gly-Ser-Glu(3-Me)-Asp(Ph(2-NH2))-(1) | 103060-53-3 | C72H101N17O26 |
|
—— | Ionomycin | 56092-81-0 | C41H72O9 |
|
—— | decanoyl-Trp-Asn-Asp-Thr(1)-Gly-Orn-Asp-D-Ala-Asp-Gly-D-Ser-Glu(3S-Me)-Asp(Ph(2-NH2))-(1) | 103060-53-3 | C72H101N17O26 |
|
—— | cis-2,6-dimethyl-4-((S)-2-methyl-3-(4-(tert-pentyl)phenyl)propyl)morpholine | 78613-35-1 | C21H35NO |
|
—— | sulfaquinoxaline sodium salt | 967-80-6 | C14H11N4O2S*Na |
|
—— | decanoyl-Trp-Asn-Asp-DL-Thr(1)-Gly-Orn-Asp-D-Ala-DL-Asp-Gly-D-Ser-Glu(3R-Me)-DL-Asp(Ph(2-NH2))-(1) | 103060-53-3 | C72H101N17O26 |
|
—— | 1-[4-[4-[[(2S)-2-(2,4-Dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone | 65277-42-1 | C26H28Cl2N4O4 |
|
—— | (Z)-Lanoconazole | 101530-10-3 | C14H10ClN3S2 |
|
—— | Imipenem-cilastatin sodium | 85960-17-4 | C28H42N5NaO9S2 |
|